Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study
Authors
Keywords
-
Journal
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
Volume 46, Issue 12, Pages 838-845
Publisher
Informa UK Limited
Online
2014-09-17
DOI
10.3109/00365548.2014.947318
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial
- (2014) JE Lake et al. HIV MEDICINE
- Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure
- (2014) Marie-Anne Vandenhende et al. PLoS One
- Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events
- (2013) Antonella d’Arminio Monforte et al. AIDS
- Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients
- (2013) A Jansen et al. HIV MEDICINE
- Effects of Switching From Efavirenz to Raltegravir on Endothelial Function, Bone Mineral Metabolism, Inflammation, and Renal Function
- (2013) Samir K. Gupta et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Decreases in Inflammatory and Coagulation Biomarkers Levels in HIV-Infected Patients Switching from Enfuvirtide to Raltegravir: ANRS 138 Substudy
- (2013) Erika F. Silva et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
- (2013) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review
- (2013) Clay Bavinger et al. PLoS One
- Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy
- (2013) Marc Noguera-Julian et al. Virology Journal
- Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature
- (2013) Amit C Achhra et al. AIDS Research and Therapy
- Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
- (2012) Esteban Martínez et al. AIDS
- Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population
- (2012) Alison J. Rodger et al. AIDS
- Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks
- (2012) Judith A. Aberg et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results
- (2012) Michael J. Kozal et al. HIV CLINICAL TRIALS
- A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults
- (2012) Dianne Carey et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing
- (2012) Daniele Armenia et al. JOURNAL OF INFECTIOUS DISEASES
- Switching Virally Suppressed, Treatment-Experienced Patients to a Raltegravir-Containing Regimen Does Not Alter Levels of HIV-1 DNA
- (2012) Yu Ming Paul Lam et al. PLoS One
- Switching between raltegravir resistance pathways analyzed by deep sequencing
- (2011) Rithun Mukherjee et al. AIDS
- Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study
- (2011) Nico Reinsch et al. European Journal of Preventive Cardiology
- HIV transmission and high rates of late diagnoses among adults aged 50 years and over
- (2010) Ruth D Smith et al. AIDS
- Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population
- (2010) Sylvie Lang et al. AIDS
- Pharmacokinetics and Pharmacogenomics of Once-Daily Raltegravir and Atazanavir in Healthy Volunteers
- (2010) M. Neely et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals
- (2010) Li Zhu et al. ANTIVIRAL THERAPY
- Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus–Infected PatientsA Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4Antiretroviral Drugs, Risk of MI, and HIV
- (2010) Sylvie Lang ARCHIVES OF INTERNAL MEDICINE
- Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir
- (2010) Rumi Minami et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Unknown
- (2010) JOURNAL OF INFECTIOUS DISEASES
- Exposure-Related Effects of Atazanavir on the Pharmacokinetics of Raltegravir in HIV-1-Infected Patients
- (2010) Dario Cattaneo et al. THERAPEUTIC DRUG MONITORING
- Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: Predictors of virological response and drug resistance evolution in a multi-cohort study
- (2009) S. Di Giambenedetto et al. INFECTION
- Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects
- (2008) Marian Iwamoto et al. CLINICAL INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started